Current times call for doubling-down on collaboration, and we wanted to take a moment and recognize the efforts of Distalmotion employees who are bringing their engineering skills to a collaborative project aiming at easing the current pressure on Intensive Care Units. READ MORE
Dexter validation confirms Distalmotion surgical robot is safe for use and meets surgeons and nurses expectations Around 20 surgeons and 20 nurses from leading European hospitals, across urology, gynaecology and general surgery participated in Dexter validation end of February and early March 2020 Surgical teams successfully performed surgical procedures using Dexter, including draping, docking, suturing, …
Craig Erickson, MD is Professor and psychiatrist at the Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine- Affiliated. He brings 15 years of experience in clinical trials in the field of neurodevelopmental disorders (NDDs), including autism spectrum disorders (ASD). He is also the principal investigator of STALICLA’s STP1 trial. In this interview, …
From Singapore to Switzerland, there’s only one way to stop fraud Read More »
GENEVA–(BUSINESS WIRE)–STALICLA SA, a near clinical stage Swiss Biotech company leading the field of precision medicine for Neurodevelopmental Disorders (NDDs) – including conditions like Autism Spectrum Disorder (ASD) or Developmental Delay – today announced the successful closure of the second tranche of its series A for an amount of USD 8M (CHF 7.7M). The round …
SEATTLE, Jan. 23, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has added Daniel Bertholet to the Board of Directors. “We are very excited to have Daniel Bertholet join our Board of Directors,” stated Clark Tedford, Ph.D., President and CEO. …
LumiThera Adds Daniel Bertholet to Board of Directors Read More »
SOPHiA Whole Exome Solution (WES) now includes accurate CNV detection, making it a powerful application for healthcare professionals in their fight against rare diseases. Houston, Texas, USA – 18th October 2019: SOPHiA GENETICS, leader in Data-Driven Medicine, announced today at the American Society of Human Genetics Annual Meeting (ASHG) the release of the new version …
SOPHiA GENETICS Reaches New Analytical Heights with its Whole Exome Solution Read More »
Neurobiologist with ten years’ Autism Spectrum Disorder experience takes on the lead research strategy role at the Swiss biotech. Geneva & Barcelona – STALICLA is delighted to announce the appointment of Stéphane Baudouin as Chief of Science effective from October 10, 2019. Stéphane takes over as Chief of Science from Luigi Boccuto, who will continue as Assistant …
STALICLA appoints Stéphane Baudouin as Chief of Science Read More »
STALICLA’S CEO & Founder, Lynn Durham invited as a speaker to the Royal Netherlands Academy of Arts and Sciences Colloquium on Neurodevelopmental Disorders – October 2-3 2019 Lynn Durham has been invited as a speaker together with a group of world leading experts at the prestigious Royal Netherlands Academy to participate in its Colloquium entitled “A …
STALICLA to present at the SACHS Associates Biotech in Europe Forum, Basel – September 25-26 CEO, Lynn Durham, will represent STALICLA at the 19thAnnual Biotech in Europe Forum. Lynn will be speaking on day 1, with a company presentation (14:00 – 14:15 CET, 25thSeptember) and as a Panellist on the Neurosciences Panel 1 (16:05 – …
